
Microbot Medical Reports Third-Quarter 2026 Results, Highlights LIBERTY System Adoption and Commercial Expansion
Microbot Medical, a medical technology company developing and distributing the LIBERTY® Endovascular Robotic System, has announced the filing of its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2026, with the U.S. Securities and Exchange Commission (SEC). Alongside the regulatory filing, the company highlighted its operational progress, commercial developments, customer adoption, manufacturing improvements and international expansion during the quarter. The update provides an overview of Microbot Medical’s progress as it continues introducing the LIBERTY System to healthcare providers in the United States and international markets.
During the third quarter, Microbot Medical reported revenue of $72,000, compared with $241,000 in the second quarter ended June 30, 2026. The sequential decline was attributed to several factors, including the timing of customer reorders and the seasonal impact of the third quarter, when activity may be lower during the summer months. The company also pointed to the hospital purchasing process as an important factor affecting the pace of new customer additions. Since the LIBERTY System’s full market release began approximately six months ago, several potential hospital accounts remain in the Value Analysis Committee (VAC) review process.
Despite the lower quarterly revenue, Microbot Medical reported encouraging developments in procedure utilization, repeat customer purchases and the expansion of its commercial network. The company ended the third quarter with 12 customer accounts, compared with 10 at the end of the previous quarter. It also reported that procedure utilization increased by 44% sequentially, indicating higher use of the LIBERTY System within its existing customer accounts. These developments form part of the company’s broader efforts to establish the robotic system in the peripheral endovascular procedures market.
Microbot Medical Reports Third-Quarter Revenue of $72,000
Microbot Medical reported revenue of $72,000 for the third quarter ended September 30, 2026. This represented a decrease from the $241,000 reported during the second quarter. The company explained that the decline reflected several business factors rather than a single issue, including customer reorder timing and seasonal patterns that affected activity during the summer months.
The timing of customer purchases can influence quarterly revenue, particularly while a medical technology product is still building its commercial presence. In Microbot Medical’s case, the LIBERTY System entered its full market release approximately six months before the reported quarter. As a result, the company is continuing to develop its customer base and work through hospital purchasing and approval procedures.
The company also highlighted the role of Value Analysis Committees in the hospital procurement process. These committees typically review medical products before they are approved for use within a hospital or healthcare system. According to Microbot Medical, the VAC process generally takes approximately four to six months. Several potential new accounts were still undergoing this review process during the third quarter.
Microbot Medical believes that gaining approval through a hospital system’s VAC process could create opportunities for wider adoption across healthcare networks with multiple hospitals. Once a product receives the necessary approval within a healthcare system, the company believes that access to additional hospitals within that network could accelerate over time. However, the timing and extent of any broader adoption will depend on the progress of individual hospital reviews and purchasing decisions.
Repeat Customer Orders Reflect Continued Demand
One of the important developments highlighted by Microbot Medical was the reorder activity among its existing customers. The company reported that 100% of current customers who exhausted their initial inventory had reordered multiple systems. Microbot Medical said this purchasing activity reflects high customer satisfaction and is consistent with the results of a company-conducted customer survey.
Repeat orders are an important commercial indicator for medical technology companies because they demonstrate that customers are continuing to purchase a product after their initial introduction. For Microbot Medical, the reported reorder activity provides an indication of continued engagement among customers who have used their initial LIBERTY System inventory.
The company also reported increased procedure utilization within existing accounts during the third quarter. This suggests that the system was being used more frequently by its current customers as the commercial rollout continued. Microbot Medical is using these developments as part of its assessment of customer adoption and the potential for further market expansion.
While repeat orders and increased utilization are encouraging indicators, the company’s quarterly revenue remained affected by purchasing timing and the ongoing hospital approval process. Microbot Medical’s commercial progress will therefore continue to depend on adding new accounts, increasing procedure activity and converting potential hospital customers into active users.
LIBERTY Procedure Utilization Increases 44%
Microbot Medical reported that the number of procedures performed using the LIBERTY Endovascular Robotic System increased by 44% in the third quarter compared with the second quarter. The increase represents one of the company’s key operational developments for the reporting period.
Procedure utilization provides a measure of how frequently the system is being used by healthcare providers. As more procedures are performed within existing customer accounts, the company has opportunities to build familiarity with the technology and strengthen its relationships with hospitals and physicians.
The company also reported that customers have used LIBERTY across several types of peripheral intervention procedures. These include Prostatic Artery Embolization (PAE), Y-90 Radioembolization, Genicular Artery Embolization (GAE) and Uterine Artery Embolization (UAE). Microbot Medical believes this range of applications supports its positioning of LIBERTY as a platform that can be used across multiple peripheral intervention procedures.
The use of the system in different procedure categories is relevant to the company’s commercial strategy because it demonstrates the range of clinical applications being explored by its customers. Rather than focusing on a single procedure type, Microbot Medical is seeking to establish LIBERTY across multiple areas of peripheral endovascular intervention.
Customer Network Expands to 12 Accounts
Microbot Medical ended the third quarter with 12 customer accounts, compared with 10 customer accounts at the end of the second quarter. The addition of two accounts reflects continued progress in the company’s efforts to expand its commercial presence in the United States.
Among the new customer developments was the adoption of the LIBERTY System by an academic medical center in North Carolina. This institution became the company’s second health system in the state to use the technology. The addition strengthens Microbot Medical’s presence in North Carolina and adds another healthcare organization to its growing customer network.
The company also announced that its first West Coast customer, located in California, became its first customer operating an Office-Based Lab (OBL). This represents an additional milestone in the commercial rollout because it extends the system’s presence to a new geographic region and a different type of healthcare setting.
Office-Based Labs provide a setting for certain outpatient procedures, and the California customer’s adoption represents Microbot Medical’s first commercial placement in this category. The company did not provide further details about the specific procedures planned at this location in the announcement.
Together, the North Carolina and California developments demonstrate the company’s efforts to broaden the geographical and organizational reach of the LIBERTY System.
Sales Territory Expansion Supports Commercial Growth
Alongside the increase in customer accounts, Microbot Medical expanded its sales organization during the third quarter. The company added two sales territories, bringing its total to 10 territories. It also stated that it plans to increase the number of sales territories to 12 by the end of 2026.
Expanding the sales territory network is part of the company’s strategy to support commercial activity and reach additional healthcare providers. A broader sales presence can help the company engage with hospitals, academic medical centers and Office-Based Labs as it works to introduce the LIBERTY System to more potential customers.
The planned increase to 12 territories represents a further step in the company’s commercial expansion strategy. As additional territories are established, Microbot Medical expects to continue developing its customer network and supporting existing accounts.
The company’s progress in adding customer accounts and expanding its sales territories comes during the early stages of the LIBERTY System’s full market release. The company will continue to work through hospital evaluation processes and commercial discussions as it seeks to expand adoption.
Manufacturing Improvements and Gross Margin Challenges
Microbot Medical reported a negative gross margin during the third quarter, as anticipated. The company explained that cost of goods sold increased by 24% compared with the second quarter. One of the main factors contributing to the increase was an inventory write-down recognized after measuring inventory at the lower of cost and net realizable value.
The company also explained that its first-in, first-out (FIFO) inventory accounting method affected the cost of systems sold during the quarter. Under this method, the inventory sold during the third quarter primarily reflected units manufactured in earlier periods, when production costs were higher. As a result, the cost associated with those units adversely affected the quarter’s gross margin.
Despite these pressures, Microbot Medical reported that the manufacturing cost per unit for systems produced during the third quarter continued to decline compared with previous quarters. The company attributed this progress to improvements in manufacturing efficiency.
The reduction in manufacturing costs is an important part of Microbot Medical’s longer-term commercial strategy. As production becomes more efficient, the company expects to improve the economics of manufacturing its robotic systems. It also plans to continue implementing cost-reduction initiatives and intends to add a second manufacturing line.
Microbot Medical believes that these measures, if completed as planned, could further reduce manufacturing costs and enable the company to achieve a positive gross margin during 2027. This is a company expectation rather than a confirmed outcome, and its achievement will depend on the progress of the planned initiatives and other business factors.
Approximately $62 Million in Cash and Marketable Securities
Microbot Medical ended the third quarter with approximately $62 million in cash, cash equivalents and marketable securities. The company said this financial position enables it to continue executing its commercial strategy in the United States and internationally.
The available funds are relevant as Microbot Medical continues working to expand its customer base, develop its sales territories, support manufacturing improvements and pursue international commercial opportunities. The company is also progressing through hospital approval processes and building relationships with healthcare providers.
The reported cash and marketable securities position provides information about the company’s financial resources at the end of the third quarter. However, the announcement did not provide a detailed breakdown of future spending or a specific timeline for the use of these funds.
International Expansion Through Distribution Agreement in Israel
Microbot Medical also reported progress in its international commercialization strategy. Following regulatory approval from the Israeli Ministry of Health’s AMAR Division, the company entered into a three-year exclusive distribution agreement with Medtechnica Ltd. to market and sell the LIBERTY System in Israel.
The agreement represents an important step in the company’s efforts to expand beyond the United States. Through the partnership, Medtechnica will serve as the exclusive distributor for the LIBERTY System in the Israeli market during the agreement period.
Microbot Medical currently expects to receive initial orders under the agreement during the fourth quarter of 2026. The expected orders would represent an initial commercial step following regulatory approval and the establishment of the distribution arrangement.
The company did not disclose the expected value or volume of the initial orders. Nevertheless, the agreement adds Israel to the list of international markets where Microbot Medical is pursuing opportunities for the LIBERTY System.
Patent Portfolio Expands Across Multiple Countries
Intellectual property development was another area of progress during and after the third quarter. Microbot Medical reported receiving new patents in the United States, Japan, China and Canada.
As of the date of the announcement, the company held 44 issued patents and 49 pending patent applications. This portfolio reflects the company’s ongoing efforts to protect its technology and support its development activities across different markets.
Patents and pending applications form part of the intellectual property position of medical technology companies. They can help protect innovations and provide a foundation for future product development and commercialization. The newly received patents across several countries add to Microbot Medical’s existing portfolio.
The company did not provide details about the specific inventions covered by each new patent in the announcement. Its reported total of issued patents and pending applications nevertheless highlights the continued development of its intellectual property portfolio.
ISO Certificate Surveillance Audit Successfully Completed
Microbot Medical also confirmed that it successfully completed its ISO certificate surveillance audit. This represents another operational milestone reported during the quarter and reflects the company’s ongoing quality-system oversight.
Surveillance audits are part of maintaining certification under applicable ISO standards. The successful completion of the audit was included among the company’s third-quarter and recent operational highlights. The announcement did not specify additional findings or provide further details about the audit process.
CEO Highlights Commercial Progress Since Full Market Release
Harel Gadot, CEO, President and Chairman of Microbot Medical, said the company was encouraged by the quality of customers added in less than six months since the LIBERTY System’s full market release. He also pointed to repeat purchases as an indication of customer satisfaction.
Gadot acknowledged that third-quarter revenue was influenced in part by seasonal activity and the hospital Value Analysis Committee process. However, he said the company believes the progress achieved during the year positions it for potential milestones in the coming months in both the United States and international markets.
His comments reflect the company’s focus on customer adoption, commercial expansion and continued development of its international presence. The management team is also monitoring the impact of hospital purchasing timelines on the pace at which potential new accounts become active customers.
LIBERTY System Designed for Peripheral Endovascular Procedures
The LIBERTY Endovascular Robotic System is described by Microbot Medical as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. It is designed to support precise vascular navigation while aiming to reduce radiation exposure and physical strain.
The system is central to Microbot Medical’s commercial strategy and its efforts to expand its presence in the medical robotics market. Its use across PAE, Y-90 Radioembolization, GAE and UAE procedures demonstrates the range of applications reported by the company’s customers.
As adoption develops, Microbot Medical is working to increase customer accounts, expand procedure utilization and establish additional sales territories. The company is also pursuing international distribution opportunities and manufacturing improvements intended to support its longer-term commercial plans.
Microbot Medical Looks Ahead to Further Commercial Milestones
Microbot Medical’s third-quarter update presents a mixed picture of financial performance and operational progress. Revenue declined sequentially to $72,000, and the company reported a negative gross margin due to inventory-related factors and higher costs associated with previously manufactured systems. At the same time, procedure utilization increased by 44%, customer accounts grew from 10 to 12, and all customers who exhausted their initial inventory reordered multiple systems.
The company also reported progress in manufacturing efficiency, international distribution, intellectual property development and quality-system oversight. With approximately $62 million in cash, cash equivalents and marketable securities at quarter-end, Microbot Medical said it remains positioned to continue executing its commercial strategy.
Looking ahead, the company plans to expand its sales territories to 12 by the end of 2026, expects initial orders under its Israeli distribution agreement during the fourth quarter of 2026, and believes ongoing cost-reduction initiatives and a planned second manufacturing line could help it achieve positive gross margin during 2027. These remain forward-looking expectations, but they outline the company’s priorities as it continues working to increase adoption of the LIBERTY Endovascular Robotic System in the United States and international markets.
Source link: https://ir.microbotmedical.com/





